Schizophrenia, obesity, and antipsychotic medications: What can we do?

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 18-33

  Citrome, Leslie ^a,c   Vreeland, Betty ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antipsychotic agents; Metabolic syndrome; Obesity; Schizophrenia; Weight gain

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CLOZAPINE; DEXAMPHETAMINE; FAMOTIDINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; LING GUI ZHU GAN TANG; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PERPHENAZINE; PHENYLPROPANOLAMINE; PLACEBO; QUETIAPINE; REBOXETINE; RIMONABANT; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; ARTICLE; BARIATRIC SURGERY; BEHAVIOR THERAPY; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DIARRHEA; DIET; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FLATULENCE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PHYSICAL ACTIVITY; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; STEATORRHEA; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; ADULT; CHILD; DRUG EFFECT; FEMALE; LIFESTYLE; MALE; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; HUMANS; LIFE STYLE; MALE; OBESITY; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 54049091644     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1786     Document Type: Article

References (100)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523-1529. (Pubitemid 29504045)
2. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26(1):137-141. (Pubitemid 34098681)
3. Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad Med. 2005;117(2):25-36. (Pubitemid 40261963)
4. Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med. 2004;116(4):49-63. (Pubitemid 39411108)
5. Citrome L, Volavka J. Atypical antipsychotics: revolutionary or incremental advance? Expert Rev Neurother. 2002;2(1):69-88. (Pubitemid 34625472)
6. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57. (Pubitemid 38030344)
7. Bray GA. Evaluation of obesity. Who are the obese? Postgrad Med. 2003;114(6):19-38. (Pubitemid 37517734)
8. Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol. 2005;19(6 suppl):84-93. (Pubitemid 44567862)
9. Tan C E, Ma S, Wai D, Chew S K, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27(5):1182-1186. (Pubitemid 38579787)
10. Anuurad E, Shiwaku K, Nogi A, et al. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health. 2003;45(6):335-343. (Pubitemid 38036188)
11. James PT, Rigby N, Leach R;International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004;11(1):3-8. (Pubitemid 38388918)
12. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.
13. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-220. (Pubitemid 29193917)
14. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. (Pubitemid 41587460)
15. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22. (Pubitemid 44234064)
16. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193-220. (Pubitemid 36321747)
17. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. (Pubitemid 29517559)
18. McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 2003;48(10):689-694. (Pubitemid 37522542)
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. (Pubitemid 41345943)
20. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006;60(8):933-940. (Pubitemid 44082284)
21. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412-419.
22. Citrome L. The effectiveness criterion: balancing efficacy against the risk of weight gain. J Clin Psychiatry. 2007;68(suppl 12):12-17. (Pubitemid 350021618)
23. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 2006;163(4):611-622. (Pubitemid 44464570)
24. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930-1941. (Pubitemid 43293215)
25. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595-600. (Pubitemid 37443191)
26. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391-399. (Pubitemid 36469941)
27. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255-258. (Pubitemid 40685790)
28. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3):316-320. (Pubitemid 43804625)
29. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100. (Pubitemid 32199865)
30. Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007;68(4):597-603. (Pubitemid 46663043)
31. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol. In press.
32. Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003;64(3):316-320. (Pubitemid 36457330)
33. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-246. (Pubitemid 27325811)
34. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863-867.
35. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002;53(7):842-847. (Pubitemid 34742766)
36. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687-700. (Pubitemid 46816822)
37. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res., 2007;93(1-3):90-98. (Pubitemid 46817931)
38. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. (Pubitemid 47121394)
39. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
40. American Diabetes Association;Amcrican Psychiatric Association; American Association of Clinical Endocrinologists: North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
41. Harmatz MG, Lapuc P. Behavior modification of overeating in a psychiatric population. J Consult Clin Psychol. 1968;32(5):583-587.
42. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv. 2007;58(4):544-550. (Pubitemid 46646525)
43. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008;41(1):17-23.
44. Alvarez-Jiménez M, González-Blanch C, Vázquez- Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry. 2006;67(8):1253-1260. (Pubitemid 44439698)
45. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003;35(3):237-241. (Pubitemid 38591665)
46. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry. 2005;39(6):479-486. (Pubitemid 40932626)
47. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003;54(8):1155-1157. (Pubitemid 36951518)
48. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004;65(4):471-477.
49. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv. 2001;52(7):967-969. (Pubitemid 32634719)
50. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(2):205-212. (Pubitemid 40314327)
51. Kwon JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry. 2006;67(4):547-553. (Pubitemid 43764231)
52. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res. 2006;83(1):95-101.
53. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007;91(13):169-177. (Pubitemid 46320905)
54. Brown S, Chan K. A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. Journal of Mental Health. 2006;15(5):543-549. (Pubitemid 44521869)
55. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res. 2006;86(1-3):36-44. (Pubitemid 44234047)
56. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self control program. Psychol Rep. 1980;46(2):483-486.
57. National Heart Lung and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000.
58. Tsai AG, Wadden TA,Womble LG, Byrne KJ. Commercial and self-help programs for weight control. Psychiatr Clin North Am. 2005;28(1):171-192. (Pubitemid 40279031)
59. Dansinger ML, Gleason JA, Griffith, JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53. (Pubitemid 40066698)
60. Poole Hoffmann V, Ahl J, Meyers A, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 2005;66(12):1576-1579. (Pubitemid 43068698)
61. Vreeland B, Toto AM, Sakowitz M. Solutions for Wellness. Ed 3. Indianapolis, IN: Eli Lilly and Co, 2008. In press.
62. Hill JO, Wyatt HR. Small changes: a big idea for addressing obesity. Obesity Mgmt. 2006;2(6):227-231. (Pubitemid 46175481)
63. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):706-711.
64. Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002;22(1):68-70. (Pubitemid 34101295)
65. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162(5):954-962. (Pubitemid 40676209)
66. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115(2):101-105. (Pubitemid 46114870)
67. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007;9(4):426-434. (Pubitemid 46865373)
68. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706-1713. (Pubitemid 350100788)
69. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull. 2007;33(3):654-656. (Pubitemid 47343724)
70. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007;(1):CD005148.
71. Baptista T, Uzcátegui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 2008;159(1-2):250-253.
72. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162(9):1744-1746. (Pubitemid 41318248)
73. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15(1):13-21. (Pubitemid 39574395)
74. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(2):81-85. (Pubitemid 36321748)
75. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol. 2003;18(6):457-461. (Pubitemid 37038342)
76. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol. 2004;19(1):37-40. (Pubitemid 38159274)
77. Assunção SS, Ruschel SI, Rosa Lde C, et al. Weight gain management in patterns with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr. 2006;28(4):270-276. (Pubitemid 46168854)
78. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol. 2004;14(4):332-336. (Pubitemid 38649091)
79. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352-358.
80. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185-193.
81. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072-2079. (Pubitemid 46114226)
82. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006;51(3):192-196.
83. Baptista T, Rangel N, Fernández V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007;93(1-3):99-108. (Pubitemid 46839067)
84. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28(4):169-175. (Pubitemid 41134243)
85. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizoph Res. 2006;82(1):115-117. (Pubitemid 43202654)
86. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(3):211-217. (Pubitemid 40685783)
87. Egger C, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol. 2007;27(5):475-478. (Pubitemid 47415045)
88. Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-448. (Pubitemid 46701583)
89. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(2):297-302. (Pubitemid 41110455)
90. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a doable-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatiy. 2002;159(6):1058-1060. (Pubitemid 34586958)
91. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003;28(3):527-529.
92. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatiy. 2004;65(6):766-771.
93. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry. 2002;63(4):345-348. (Pubitemid 34456363)
94. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry. 1988;153:208-213. (Pubitemid 18191225)
95. Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA. 1965;193:95-98.
96. Ding G, Yu G, Zhang J, et al. The therapeutic effects of ling gui zhu gan tang mixture in 50 psychotic patients with obesity induced by the psychoactive drugs. J Tradit Chin Med. 2005;25(1):25-28. (Pubitemid 41065187)
97. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? J Clin Psychiatry. 2004;65(8):1145.
98. Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg. 2004;14(3):349-352. (Pubitemid 38407011)
99. Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg. 2004;14(9):1148-1156. (Pubitemid 39458586)
100. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr. 1998;68(4):899-917.